Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1613
Full metadata record
DC FieldValueLanguage
dc.contributorPilgrim, Charles H.en_US
dc.contributorte Marvelde, Lucen_US
dc.contributorStuart, Ellaen_US
dc.contributorCroagh, Danen_US
dc.contributorDeutscher, Daviden_US
dc.contributorNikfarjam, Mehrdaden_US
dc.contributorLee, Belindaen_US
dc.contributorChristophi, Christopheren_US
dc.date.accessioned2020-11-23T06:13:13Z-
dc.date.available2020-11-23T06:13:13Z-
dc.date.issued2020-
dc.identifier.govdoc01567en_US
dc.identifier.urihttp://hdl.handle.net/11054/1613-
dc.description.abstractBackground The Victorian Pancreas Cancer summit 2017 analysed state‐wide data on management of Victorians with pancreas cancer between 2011 and 2015 to identify variations in care and outcomes. Pancreas cancer remains a formidable disease but systemic therapies are increasingly effective. Surgery remains essential but insufficient alone for cure. Understanding patterns of care and identifying variations in treatment is critical to improving outcomes. Methods This population‐based study analysed data collected prospectively by Department of Health and Human services (Victorian state government). Data were extracted from Victorian Cancer Registry (covering all Victorian cancer diagnoses), Victorian Admitted‐Episodes Dataset (all inpatient data), Victorian Radiotherapy Minimum Dataset and Victorian Death Index providing demographics, tumour and treatment characteristics, age‐standardized incidence, overall and median survival. Results Of 3962 Victorian patients with any form of pancreatic malignancy, 82% were ductal adenocarcinoma (PDAC), of whom 67% had metastases at diagnosis. One‐year overall survival for PDAC was 30% (60% non‐metastatic, 15% if metastatic). Median survival with metastases increased from 2.7 to 3.9 months, and from 13.3 to 15.9 months for non‐metastatic PDAC between 2011 and 2015. Thirty‐one percent of non‐metastatic patients underwent pancreatectomy. About 1.5% were treated with neoadjuvant chemotherapy/chemoradiation. Of patients undergoing intended curative resection, 77% proceeded to adjuvant therapy. Fifty‐one percent of metastatic PDAC patients never received anti‐tumour therapy. Conclusions Nearly one‐fourth of surgically treated patients never received systemic therapy. More than two‐thirds of non‐metastatic patients never proceeded to surgery. Further consideration of neoadjuvant therapy should be given to borderline resectable patients. Most patients with PDAC still die soon after diagnosis, but median survival is increasing.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2020-10-13T00:24:37Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2020-11-23T06:13:13Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2020-11-23T06:13:13Z (GMT). No. of bitstreams: 0 Previous issue date: 2020en
dc.titlePopulation‐based analysis of treatment patterns and outcomes for pancreas cancer in Victoria.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.bibliographicCitation.titleHepatopancreaticobiliary Surgeryen_US
dc.bibliographicCitation.volume90en_US
dc.bibliographicCitation.issue9en_US
dc.bibliographicCitation.stpage1677en_US
dc.bibliographicCitation.endpage1682en_US
dc.subject.healththesaurusHEPATOPANCREATICOBILIARY SURGERYen_US
dc.subject.healththesaurusPANCREASen_US
dc.subject.healththesaurusSURGICAL ONCOLOGYen_US
dc.identifier.doihttps://doi.org/10.1111/ans.15721en_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.